Recently launched at the Radiological Society of North America (RSNA) conference, the SIGNA Experience reportedly features synergistic technologies and artificial intelligence (AI) advances that help improve the efficiency and quality of magnetic resonance imaging.
Offering the potential benefits of streamlined scanning and intelligent automation in magnetic resonance imaging (MRI), GE Healthcare recently launched the SIGNA Experience, which combines imaging software, artificial intelligence (AI) applications and automated workflow technologies into one platform.
GE Healthcare said the four primary components of the SIGNA Experience include enhanced image quality through the next-generation imaging software SIGNA One (available on SIGNA Prime); deep learning AI applications (including AIR Recon DL) that facilitate shorter scan times and improved signal-to-noise (SNR) ratios; flexible, lightweight AIR Coils; and automated workflow technologies, such as AIRTouch, that simplify scan set-up.
The SIGNA Experience also offers visually highlighted fields for step-by-step guidance, minimal clicks to complete the MRI exam and an intuitive workflow that accommodates a variety of experience levels, according to GE Healthcare.
“SIGNA Experience was designed in response to today’s industry pressures to help achieve operational efficiency and simplicity as clinicians face a significant volume of non-urgent backlog scans caused largely by the impact of COVID-19, radiologist shortages and staff burnout,” explained Jie Xue, the president, and CEO of Magnetic Resonance for GE Healthcare. “These technologies enable scanner operators of all skill levels to get the job done without compromising quality and output.”
FDA Clears AI-Powered Quantitative Perfusion Mapping for Cone-Beam CT
May 6th 2024Reportedly validated in more than 10 clinical trials, the AngioFlow perfusion imaging software enables timely identification of brain regions with cerebral blood flow reduction and those with significant hypoperfusion.
Breast MRI and Dense Breasts: A Closer Look at Early Findings from a New Prospective Trial
May 2nd 2024Supplemental breast MRI had a cancer detection rate (CDR) of 20/1000 and a positive predictive value (PPV) of 50 percent, according to preliminary findings from a prospective trial involving women with heterogeneously or very dense breasts.